Italia markets closed

ProMIS Neurosciences, Inc. (PMN)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
1,8000-0,0200 (-1,10%)
In data: 12:31PM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,8200
Aperto1,8000
Denaro0,0000 x 0
Lettera0,0000 x 0
Min-Max giorno1,7300 - 1,8800
Intervallo di 52 settimane0,9500 - 8,9500
Volume1.799
Media Volume15.820
Capitalizzazione34,13M
Beta (5 anni mensile)0,68
Rapporto PE (ttm)N/D
EPS (ttm)-1,0700
Prossima data utili06 mar 2024 - 11 mar 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A8,75
  • GlobeNewswire

    ProMIS Neurosciences Closes $20.4 Million Private Placement Financing

    At-the-Market fundraise to support Company through several potentially value-creating milestones and beyondTORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 08, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple sys

  • GlobeNewswire

    ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference

    TORONTO, Ontario and CAMBRIDGE, Massachusetts, Sept. 06, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced that Gail Farfel, Ph.D., Chief Executive Officer and Larry Altstiel, M.D., Ph.D., Chief Medical Offi

  • GlobeNewswire

    ProMIS Neurosciences Announces $20.4 Million Private Placement Financing

    At-the-Market Fundraise supports Company through several potentially value-creating milestones and beyond TORONTO, Ontario and CAMBRIDGE, Massachusetts, Aug. 21, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (Nasdaq: PMN) (“ProMIS” or the “Company”), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple syste